Future research is expected to elucidate the mechanism of action HDAC inhibitors in order to design novel reagents with increased effectiveness and specificity
Blood Rev 45:100730 Cecconi S, Mauro A, Cellini V, Patacchiola F (2012) The role of Akt signalling in the mammalian ovary
Observed variability could be due to intrinsic variability of synapses (e.g., of the ratios of NMDA/AMPA receptors and calcium permeable/impermeable AMPA receptors across synapses within the same type of connection) and also to differences in experimental conditions and plasticity induction protocols (see Box 3 and Table 1) as well as animal lines and age and possible biases in sampling of highly heterogeneous inhibitory neurons
However, complete discontinuation typically results in weight regain, making CagriSema a long-term commitment requiring indefinite maintenance dosing
PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
